<DOC>
	<DOCNO>NCT00866697</DOCNO>
	<brief_summary>This study determine whether therapy pazopanib effective safe woman epithelial ovarian , fallopian tube , primary peritoneal cancer whose cancer progress first line chemotherapy .</brief_summary>
	<brief_title>Efficacy Safety Pazopanib Monotherapy After First Line Chemotherapy Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>This randomize , two-arm , placebo control , double-blind , multicenter , intergroup Phase III study woman non-bulky FIGO Stage II - IV ovarian , fallopian tube , primary peritoneal cancer progress ( i.e. , CR , PR , SD ) complete first-line chemotherapy advance ovarian cancer . Approximately 900 subject enrol study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>write informed consent At least 18 year old . Histologically confirm , FIGO stage IIIV epithelial ovarian , fallopian tube primary peritoneal carcinoma treat surgical debulking least five cycle platinumtaxane doublet chemotherapy . Study randomization least 3 week 12 week date last chemotherapy dose , major toxicity previous chemotherapy must resolve . No evidence disease progression ECOG status 0 1 . Able swallow retain oral medication . Adequate hematologic , hepatic , renal system function follow : Hematologic Absolute neutrophil count ( ANC ) least 1.5 X 10^9/L Hemoglobin least 9 g/dL ( 5.59 mmol/L ) Platelets least 100 X 10^9/L Prothrombin time ( PT ) international normalize ratio ( INR ) 1.2 X ULN Activated partial thromboplastin time ( aPTT ) 1.2 X ULN Hepatic Total bilirubin 1.5 X ULN AST ALT 2.5 X ULN Renal Serum creatinine 1.5 mg/dL Or , great 1.5 mg/dL : Calculated creatinine clearance least 50 mL/min Urine Protein Urine protein 0 , trace , +1 determine dipstick urinalysis , &lt; 1.0 gram determine 24 hour urine protein analysis . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) OR childbearing potential , agree use adequate contraception . Either ( ) bulky disease , ( b ) residual disease opinion investigator need imminent secondline therapy Synchronous primary endometrial carcinoma , past history primary endometrial carcinoma , exclude unless certain condition meet . Clinically significant gastrointestinal abnormality Prolongation correct QT interval ( QTc ) &gt; 480 msecs History one cardiovascular condition within past 6 month prior randomization Poorly control hypertension History cerebrovascular accident ( include transient ischemic attack ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month prior randomization Major surgery ( include interval debulking ) trauma within 28 day , minor surgical procedure within 7 day , prior randomization , nonhealing wound , fracture , ulcer . Evidence active bleeding bleed diathesis . Hemoptysis within 6 week prior randomization . Endobronchial metastasis . Serious and/or unstable preexist medical ( e.g. , uncontrolled infection ) , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . Investigational antiVEGF anticancer therapy prior study randomization . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>fallopian tube cancer</keyword>
	<keyword>pazopanib</keyword>
	<keyword>anti-angiogenesis</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>primary peritoneal cancer</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>gynecologic cancer</keyword>
</DOC>